Abstract
Fluorouracil (5FU) remains the primary chemotherapy agent for adenocarcinomas of the gastrointestinal tract. Toxicities are both dose and schedule dependent, and include myelosuppression, stomatitis and diarrhoea, and cutaneous manifestations. Side effects are usually easily manageable in normal clinical practice.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Diasio RB, Beavers TL, Carpenter JT (1988). Familial Deficiency of Dihydropyrimidine Dehydrogenase. J.Clin.Invest. 81: 47–51.
Zhang R, Lu Z, Lu T, Soong S-J, Diasio RB (1993). Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes. Cancer Research 53: 2816–22.
Bakkeren JAJM, De Abreu RA, Sengers RCA, Gabreels FJM, Maas JM, Renier WO (1984). Elevated urine, blood and cerebrospinal fluid levels of uracil and thymine in a child with dihydrothymine dehydrogenase deficiency. Clin. Chim. Acta 140: 247–56.
Simmonds HA, Duley JA, Davies PM (1990). Analysis of purines and pyrimidines in blood, urine and other physiological fluids. In:Techniques in Diagnostic Human Biochemical Genetics, Wiley-Liss, NY, pp397–424.
Lowry OH, Rosebrough NJ, Farr A, Randall RJ (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265–75.
Henderson MJ, Jones S, Walker P, Duley JA, Simmonds HA (1995). Heterogeneity of symptomatology in two male siblings with thymine uraciluria. J. Inher. Metab. Dis. 18: 85–6.
Lu Z, Zhang R, Diasio RB (1993). Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver. Cancer Res. 53: 5433–8.
Harris BE, Carpenter JT, Diasio RB (1991). Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 68: 499–501.
Gonzalez FJ, Fernandez-Salguero P (1995). Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. TiPS 16: 325–7.
Van Gennip AH, Abeling AH, Stroomer NGGM, Van Lenthe H, Bakker HD (1994). Clinical and biochemical findings in six patients with pyrimidine degradation defects. J.Inherited Metabolic Diseases 17: 130–2.
Webster DR, Becroft DM, Suttle DP (1995). Hereditary orotic aciduria and other disorders of pyrimidine metabolism. In:The Metabolic and Molecular Bases of Inherited Disease, ed. CR Scriver, AL Beaudet, WS Sly, D Valle, chapter 55, McGraw-Hill, NY, pp 1799–1837.
Milano G, Etienne M-C (1994) Potential importance of dihydropyrimidine dehydrogenase in cancer chemotherapy. Pharmacogen. 4: 301–6.
Yokota H, Fernandez-Salguero P, Furuya H, Lin K, McBride OW, Podschun B, Schnackerz KD, Gonzalez FJ (1994). cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J. Biol. Chem. 269: 23192–6.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Duley, J.A., Nethersell, A.B.W. (1998). Delayed Hypersensitivity to 5-Fluorouracil Associated with Reduced Dihydropyrimidine Dehydrogenase (DPD) Activity. In: Griesmacher, A., Müller, M.M., Chiba, P. (eds) Purine and Pyrimidine Metabolism in Man IX. Advances in Experimental Medicine and Biology, vol 431. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5381-6_28
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5381-6_28
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7456-5
Online ISBN: 978-1-4615-5381-6
eBook Packages: Springer Book Archive